LB Pharmaceuticals

New York, United States

LB Pharmaceuticals specializes in developing LB-102 (n-Methyl amisulpride) as a treatment for schizophrenia.

$75.0M raised

Jan 2024

Series C

Biopharma Biotechnology Pharmaceutical

Top Investors

PontifaxVida VenturesTCG CrossoverDeep Track Capital

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about LB Pharmaceuticals

How much funding has LB Pharmaceuticals raised?

LB Pharmaceuticals has raised $75.0M in total funding. The most recent round was Series C. The last funding was announced in January 2024.

Who are LB Pharmaceuticals's investors?

LB Pharmaceuticals's investors include Pontifax, Vida Ventures, TCG Crossover, Deep Track Capital.

Where is LB Pharmaceuticals headquartered?

LB Pharmaceuticals is headquartered in New York, United States.

What does LB Pharmaceuticals do?

LB Pharmaceuticals specializes in developing LB-102 (n-Methyl amisulpride) as a treatment for schizophrenia.

What stage is LB Pharmaceuticals at?

LB Pharmaceuticals is at the Series C stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 24, 2024.

MLA

"LB Pharmaceuticals — Funding & Investors." VCBacked, January 24, 2024, https://www.vcbacked.co/company/lb-pharmaceuticals. Accessed June 17, 2026.

APA

VCBacked. (2024). LB Pharmaceuticals — Funding & Investors. Retrieved June 17, 2026, from https://www.vcbacked.co/company/lb-pharmaceuticals

Wikipedia (cite web)

{{cite web |title=LB Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/lb-pharmaceuticals |website=VCBacked |access-date=June 17, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 24, 2024.

Similar Companies in Biopharma